1. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
   Tieshan Teng et al, 2022, International Journal of Molecular Sciences CrossRef
2. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
   Mihaela-Simona Popoviciu et al, 2023, International Journal of Molecular Sciences CrossRef
3. GLP1-receptor-agonisták a 2-es típusú diabetes vércukorcsökkentő kezelésében
   Gábor Winkler, 2022, Orvosi Hetilap CrossRef
4. Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes
   Hoda Gad et al, 2024, Cureus CrossRef
5. Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes
   Susanna Longo et al, 2023, Acta Diabetologica CrossRef
6. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
   P. Marzullo et al, 2022, Journal of Endocrinological Investigation CrossRef
7. Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
   Angelo Maria Patti et al, 2023, Biomedicines CrossRef
8. Multidisciplinary combined treatment based on bariatric surgery for metabolic syndrome: a review article
   Jiaji Xie et al, 2024, International Journal of Surgery CrossRef
9. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
   Mariana Tilinca et al, 2021, Journal of Personalized Medicine CrossRef
10. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
    Tianyu Wang et al, 2024, Frontiers in Pharmacology CrossRef
11. Clinical Pharmacokinetics of Semaglutide: A Systematic Review
    Xi-Ding Yang et al, 2024, Drug Design, Development and Therapy CrossRef